Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Rating) – Equities researchers at Chardan Capital boosted their FY2023 earnings per share estimates for Outlook Therapeutics in a research note issued on Tuesday, May 16th. Chardan Capital analyst D. Gataulin now forecasts that the company will post earnings of ($0.18) per share for the year, up from their […]
Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Rating) – Stock analysts at Cantor Fitzgerald raised their FY2023 EPS estimates for shares of Outlook Therapeutics in a research note issued to investors on Tuesday, May 16th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($0.25) per share for the year, up from their […]
Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Rating) – Equities research analysts at Chardan Capital upped their FY2023 earnings per share (EPS) estimates for shares of Outlook Therapeutics in a report issued on Tuesday, May 16th. Chardan Capital analyst D. Gataulin now forecasts that the company will earn ($0.18) per share for the year, up from […]
Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Rating) – Research analysts at Chardan Capital issued their FY2024 earnings estimates for shares of Outlook Therapeutics in a note issued to investors on Tuesday, May 16th. Chardan Capital analyst D. Gataulin anticipates that the company will post earnings of $0.10 per share for the year. The consensus estimate […]
Vista Finance LLC lowered its position in Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Rating) by 30.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 277,615 shares of the company’s stock after selling 119,940 shares during the period. Outlook Therapeutics makes up about 0.4% of Vista Finance LLC’s portfolio, making the stock its […]